Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214571 · ClinicalTrials.gov registry record · Phase 2
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
A Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by Shionogi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT07214571: Recruiting Phase 2 study of Respiratory Syncytial Virus Infections, sponsored by Shionogi.
NCT07214571 is a Phase 2 study of Respiratory Syncytial Virus Infections that is actively recruiting participants, run by Shionogi. The registered enrollment target is 192 participants, below the 1,082-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214571, a Phase 2 study of Respiratory Syncytial Virus Infections, is actively recruiting participants, sponsored by Shionogi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG S-337395
Study Locations (20)
Florida
- Hope Clinical Trials - 3970 W Flagler St. - Coral Gables
- Beautiful Minds Clinical Research Center - Cutler Bay
- Doral Medical Research - Hialeah
- Southern Clinical Research - Miami
- LCC Medical Research - Miami - BTC - PPDS - Miami
- Nuren Medical and Research Center - Miami
- Continental Clinical Research, LLC - Miami
- Dynamic Medical Research, LLC - Miami - Miami
- Miami Clinical Research, LLP. - Miami
- Reed Medical Research - Miami
- Palm Springs Community Health Center - Miami Lakes
- Oceanic Research Group, LLC - North Miami Beach
- CDC Research Institute, LLC - Port Saint Lucie
- Cordova Research Insittute - Sweetwater
- Better Life Clinical Research LLC - Tampa
- Research Bay,Inc. - Tampa
- Santos Research Center - 5927 Webb Rd - Tampa
California
- LA Universal Research Center, Inc. - Los Angeles
- Med Partnes, Inc - Elligo- PPDS - Toluca Lake
Georgia
- Covenant Pulmonary Criticial Care and Research Ins - East Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2025-12-11 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
What NCT07214571 shows while recruiting
NCT07214571 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 1,082-participant average among 21 other Respiratory Syncytial Virus Infections trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Respiratory Syncytial Virus Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07214571 names 20 study sites across 3 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07214571 about?
NCT07214571 is a clinical study titled "A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease". The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.
What is the current status of trial NCT07214571?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2025-12-11. Estimated completion is 2026-12-30.
What conditions does trial NCT07214571 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infections.
What interventions are being tested in trial NCT07214571?
The interventions under investigation include: Placebo (DRUG), S-337395 (DRUG).
Who is sponsoring clinical trial NCT07214571?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214571 being conducted?
This trial has 20 study locations across California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07214571's enrollment target sits among peer trials
192 13th of 21 higher than 9 of 21 other Respiratory Syncytial Virus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
RECRUITING · Phase 2
-
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
COMPLETED · Phase 2
-
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
COMPLETED · Phase 2
-
A Study of BLB-201 RSV Vaccine in Infants and Children
RECRUITING · Phase 1
-
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
RECRUITING · Phase 3
-
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI